UPCOMING DEADLINE: uniQure N.V. (QURE) Securities Fraud Class Action – April 13, 2026 Lead Plaintiff Deadline - Faruqi & Faruqi LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Pivotal Study and its implications for the BLA submission timeline [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA submission for AMT-130 [5]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous statements about the path toward accelerated approval [6]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [7]. Group 2: Class Action Details - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to discuss their legal rights and consider seeking the role of lead plaintiff in the class action [3][8]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [9].